You are viewing the site in preview mode
Skip to main content
India
Mexico
Estimated U.S. cases prevented before U.S. arrival
U.S. Savings
ICER
Estimated U.S. cases prevented before U.S. arrival
U.S. savings
ICER
Base case
138
$3,155,900
$151,388
41
$598,737
$221,088
Proportion with clinical findings suggestive of TBa (decreased by 50%)
69
1,577,950
299,463
21
$299,369
$452,715
Proportion with clinical findings suggestive of TBa (increased by 50%)
NAb
NA
NA
62
$898,106
$143,879
Proportion of B1 persons diagnosed domestically (reduced by 50%)
138
$2,777,095
$154,135
41
$558,045
$222,075
Proportion of B1 persons diagnosed domestically (increased by 50%)
138
$3,534,706
$148,641
41
$639,430
$220,100
Time spent on panel physician treatment in India or Mexico (reduced by 67% of baseline)
138
$3,155,900
$42,654
41
$598,737
$189,459
Time spent on panel physician treatment in India or Mexico (increased by 67% of baseline)
138
$3,155,900
$260,665
41
$598,737
$252,875
Opportunity costs excluded
138
$499,180
Cost saving
41
$528,421
$175,200
Notes: ICER Incremental Cost-effectiveness Ratio, U.S. United States
a In the model, individuals without clinical findings suggestive of TB do not go on to sputum culture/smear testing. If we assume that same rates of diagnosis (active TB) both overseas and at domestic follow-up for immigrants and NIVs, then this single parameter affects both the number of TB cases diagnosed overseas and the number of B1s. See Appendix Section A3 for detailsb We did not evaluate a 50% increase for Indian NIVs because this did not seem plausible given
